      |
|
||||||||
|
Dr. I.J.M. de Vries
Research interest include immunotherapy of cancer. A clinical vaccination program was established in which tumor-associated antigens loaded on DCs are used to treat both melanoma and colon cancer patients. A major current project is to translate the DC vaccination into pediatric oncological clinical setting. A primary scientific interest continues along the line of DC-immunotherapy and in particular the migration and imaging of DC. |
||||||||
|
Recent key publications Benitez-Ribas, D., Tacken, P., Punt, C.J., de Vries, I.J., Figdor, C.G. Impact factor: 6.068 Activation of human plasmacytoid dendritic cells by TLR9 impairs Fc gammaRII-mediated uptake of immune complexes and presentation by MHC class II. J Immunol, 2008. 181(8): 5219-24. Meyer-Wentrup, F., Benitez-Ribas, D., Tacken, P.J., Punt, C.J., Figdor, C.G., de Vries, I.J., Adema, G.J. Targeting DCIR on human plasmacytoid dendritic cells results in antigen presentation and inhibits IFN-alpha production. Blood, 2008. 111(8): 4245-53. |
||||||||
